{
    "name": "sugammadex sodium",
    "comment": "Rx",
    "other_names": [
        "Bridion"
    ],
    "classes": [
        "Selective Relaxant Binding Agents"
    ],
    "source": "https://reference.medscape.com/drug/bridion-sugammadex-sodium-999851",
    "pregnancy": {
        "common": [
            "There are no data on use in pregnant women to inform any drug-associated risks",
            "In animal reproduction studies, there was no evidence of teratogenicity following daily IV administration to rats and rabbits during organogenesis at exposures of up to 6 and 8 times, respectively, the maximum recommended human dose (MRHD) of 16 mg/kg",
            "However, there was an increase in the incidence of incomplete ossification of the sternebra and reduced fetal body weights in rabbits"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Present in rat milk",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Known hypersensitivity to sugammadex or any of its components",
                "Hypersensitivity reactions that occurred varied from isolated skin reactions to serious systemic reactions (ie, anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Anaphylaxis and hypersensitivity: Clinicians should be prepared for the possibility of drug hypersensitivity reactions (including anaphylactic reactions) and take the necessary precautions",
                "Marked bradycardia reported, some resulting in cardiac arrest, within minutes following sugammadex administration",
                "Ventilatory support is mandatory for patients until adequate spontaneous respiration is restored and the ability to maintain a patent airway is assured",
                "A small number of patients experienced a delayed or minimal response to sugammadex; it is important to monitor ventilation until recovery occurs",
                "Lower than recommended sugammadex doses may lead to an increased risk of recurrence of neuromuscular blockade after initial reversal and is not recommended",
                "Drugs that potentiate neuromuscular blockade (eg, aminoglycosides, opioids) are used in the postoperative phase, so special attention should be paid to the possibility of recurrence of neuromuscular blockade",
                "Doses up to 16 mg/kg were associated with increased coagulation parameters (ie, aPPT, INR) of up to 25% for up to 1 hr in healthy volunteers; in patients undergoing major orthopedic surgery of the lower extremity who were concomitantly treated with heparin or LMWH for thromboprophylaxis, increases in aPTT and PT (INR) of 5.5% and 3%, respectively, were observed in the hour following sugammadex 4 mg/kg",
                "Not recommended for patients with severe renal impairment (CrCl <30 mL/min) and those on dialysis",
                "In clinical trials when neuromuscular blockade was intentionally reversed in the middle of anesthesia, the following signs of light anesthesia were observed: movement, coughing, grimacing, and suckling of the tracheal tube",
                "Has not been studied for reversal following rocuronium or vecuronium administration in the ICU setting",
                "Do not use to reverse blockade induced by nonsteroidal neuromuscular blocking agents (eg, succinylcholine, benzylisoquinolinium compounds)",
                "Risk of adverse reactions may be greater in patients with impaired renal function; care should be taken in the elderly when selecting dose, may be useful to monitor renal function",
                "Do not use to reverse neuromuscular blockade induced by steroidal neuromuscular blocking agents other than rocuronium or vecuronium"
            ],
            "specific": [
                {
                    "type": "Waiting times for readministration of NBA following reversal with sugammadex",
                    "description": [
                        "Minimum waiting time for 1.2 mg/kg rocuronium: 5 minutes",
                        "When rocuronium 1.2 mg/kg is administered within 30 minutes after reversal with sugammadex, the onset of neuromuscular blockade may be delayed up to ~4 minutes and the duration of neuromuscular blockade may be shortened up to approximately 15 minutes",
                        "Minimum waiting time for 0.6 mg/kg rocuronium or 0.1 mg/kg vecuronium (normal renal function): 4 hr; if a shorter waiting time is required, the rocuronium dose for a new neuromuscular blockade should be 1.2 mg/kg",
                        "Minimum waiting time for 0.6 mg/kg rocuronium or 0.1 mg/kg vecuronium (mild-to-moderate renal impairment): 24 hr",
                        "Rocuronium readministration or vecuronium administration after reversal of rocuronium with sugammadex 16 mg/kg",
                        "Waiting time of 24 hr is suggested",
                        "If neuromuscular blockade is required before the recommended waiting time has elapsed, use a nonsteroidal neuromuscular blocking agent",
                        "The onset of a depolarizing neuromuscular blocking agent might be slower than expected, because a substantial fraction of postjunctional nicotinic receptors can still be occupied by the neuromuscular blocking agent"
                    ]
                },
                {
                    "type": "Drug interaction overview ",
                    "description": [
                        "Toremifene has a relatively high binding affinity for sugammadex, and therefore, some displacement of vecuronium or rocuronium from the sugammadex binding complex could occur and result in recurrence of neuromuscular blockade",
                        "Hormonal contraceptives",
                        "May bind to progestogen, thereby decreasing progestogen exposure",
                        "Administration of a bolus dose of sugammadex is considered to be equivalent to missing dose(s) of oral contraceptives containing an estrogen or progestogen; if an oral contraceptive is taken on the same day that sugammadex is administered, the patient must use an additional, nonhormonal contraceptive method or backup method of contraception (eg, condoms and spermicides) for the next 7 days",
                        "In the case of hormonal hormonal contraceptives not taken orally, the patient must use an additional, hormonal contraceptive method or backup method of contraception (eg, condoms and spermicides) for the next 7 days",
                        "Sugammadex may also interfere with serum progesterone assay"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "dienogest/estradiol valerate",
            "description": {
                "common": "sugammadex sodium decreases effects of dienogest/estradiol valerate by receptor binding competition. Avoid or Use Alternate Drug. In vitro binding studies showed that sugammadex may bind to progestogen, thereby decreasing progestogen exposure. Therefore, a sugammadex bolus dose is considered to be equivalent to missing dose(s) of hormonal contraceptives containing an estrogen or progestogen. If an oral contraceptive is taken on the same day of sugammadex, or the patient has a transdermal or implant hormonal contraceptive, the patient must use an additional, nonhormonal contraceptive method or back-up method of contraception (eg, condoms and spermicides) for the next 7 days."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "sugammadex sodium decreases effects of ethinylestradiol by receptor binding competition. Avoid or Use Alternate Drug. In vitro binding studies showed that sugammadex may bind to progestogen, thereby decreasing progestogen exposure. Therefore, a sugammadex bolus dose is considered to be equivalent to missing dose(s) of hormonal contraceptives containing an estrogen or progestogen. If an oral contraceptive is taken on the same day of sugammadex, or the patient has a transdermal or implant hormonal contraceptive, the patient must use an additional, nonhormonal contraceptive method or back-up method of contraception (eg, condoms and spermicides) for the next 7 days."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etonogestrel",
            "description": {
                "common": "sugammadex sodium decreases effects of etonogestrel by receptor binding competition. Avoid or Use Alternate Drug. In vitro binding studies showed that sugammadex may bind to progestogen, thereby decreasing progestogen exposure. Therefore, a sugammadex bolus dose is considered to be equivalent to missing dose(s) of hormonal contraceptives containing an estrogen or progestogen. If an oral contraceptive is taken on the same day of sugammadex, or the patient has a transdermal or implant hormonal contraceptive, the patient must use an additional, nonhormonal contraceptive method or back-up method of contraception (eg, condoms and spermicides) for the next 7 days."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levonorgestrel intrauterine",
            "description": {
                "common": "sugammadex sodium decreases effects of levonorgestrel intrauterine by receptor binding competition. Avoid or Use Alternate Drug. In vitro binding studies showed that sugammadex may bind to progestogen, thereby decreasing progestogen exposure. Therefore, a sugammadex bolus dose is considered to be equivalent to missing dose(s) of hormonal contraceptives containing an estrogen or progestogen. If an oral contraceptive is taken on the same day of sugammadex, or the patient has a transdermal or implant hormonal contraceptive, the patient must use an additional, nonhormonal contraceptive method or back-up method of contraception (eg, condoms and spermicides) for the next 7 days."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levonorgestrel oral",
            "description": {
                "common": "sugammadex sodium decreases effects of levonorgestrel oral by receptor binding competition. Avoid or Use Alternate Drug. In vitro binding studies showed that sugammadex may bind to progestogen, thereby decreasing progestogen exposure. Therefore, a sugammadex bolus dose is considered to be equivalent to missing dose(s) of hormonal contraceptives containing an estrogen or progestogen. If an oral contraceptive is taken on the same day of sugammadex, or the patient has a transdermal or implant hormonal contraceptive, the patient must use an additional, nonhormonal contraceptive method or back-up method of contraception (eg, condoms and spermicides) for the next 7 days."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "medroxyprogesterone",
            "description": {
                "common": "sugammadex sodium decreases effects of medroxyprogesterone by receptor binding competition. Avoid or Use Alternate Drug. In vitro binding studies showed that sugammadex may bind to progestogen, thereby decreasing progestogen exposure. Therefore, a sugammadex bolus dose is considered to be equivalent to missing dose(s) of hormonal contraceptives containing an estrogen or progestogen. If an oral contraceptive is taken on the same day of sugammadex, or the patient has a transdermal or implant hormonal contraceptive, the patient must use an additional, nonhormonal contraceptive method or back-up method of contraception (eg, condoms and spermicides) for the next 7 days."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "norethindrone",
            "description": {
                "common": "sugammadex sodium decreases effects of norethindrone by receptor binding competition. Avoid or Use Alternate Drug. In vitro binding studies showed that sugammadex may bind to progestogen, thereby decreasing progestogen exposure. Therefore, a sugammadex bolus dose is considered to be equivalent to missing dose(s) of hormonal contraceptives containing an estrogen or progestogen. If an oral contraceptive is taken on the same day of sugammadex, or the patient has a transdermal or implant hormonal contraceptive, the patient must use an additional, nonhormonal contraceptive method or back-up method of contraception (eg, condoms and spermicides) for the next 7 days."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "toremifene",
            "description": {
                "common": "toremifene decreases effects of sugammadex sodium by receptor binding competition. Modify Therapy/Monitor Closely. Toremifene binds to sugammadex and will likely displace some of vecuronium or rocuronium from sugammadex. The recovery to TOF ratio to 0.9 could therefore be delayed in patients who have received toremifene on the same day of surgery."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Pain",
            "percent": "36-52"
        },
        {
            "name": "Nausea",
            "percent": "23-26"
        },
        {
            "name": "Vomiting",
            "percent": "11-15"
        },
        {
            "name": "Hypotension",
            "percent": "4-13"
        },
        {
            "name": "Procedural pain",
            "percent": "58-59"
        },
        {
            "name": "Headache",
            "percent": "5-10"
        },
        {
            "name": "Pyrexia",
            "percent": "5-9"
        },
        {
            "name": "Hypertension",
            "percent": "5-9"
        },
        {
            "name": "Airway complication of anesthesia",
            "percent": "1-9"
        },
        {
            "name": "Anesthetic complication",
            "percent": "1-9"
        },
        {
            "name": "Procedural complication",
            "percent": "1-8"
        },
        {
            "name": "Cough",
            "percent": "1-8"
        },
        {
            "name": "Chills",
            "percent": "3-7"
        },
        {
            "name": "Incision site pain",
            "percent": "4-6"
        },
        {
            "name": "Abdominal pain",
            "percent": "4-6"
        },
        {
            "name": "Dizziness",
            "percent": "3-6"
        },
        {
            "name": "Pain in extremity",
            "percent": "1-6"
        },
        {
            "name": "QT interval abnormal",
            "percent": "1-6"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "3-5"
        },
        {
            "name": "Insomnia",
            "percent": "2-5"
        },
        {
            "name": "Tachycardia",
            "percent": "2-5"
        },
        {
            "name": "Bradycardia",
            "percent": "1-5"
        },
        {
            "name": "Pruritus",
            "percent": "2-3"
        },
        {
            "name": "Flatulence",
            "percent": "1-3"
        },
        {
            "name": "Hypoesthesia",
            "percent": "1-3"
        },
        {
            "name": "Anxiety",
            "percent": "1-3"
        },
        {
            "name": "Wound hemorrhage",
            "percent": "1-2"
        },
        {
            "name": "Dry mouth",
            "percent": "1-2"
        },
        {
            "name": "Restlessness",
            "percent": "1-2"
        },
        {
            "name": "Depression",
            "percent": "1-2"
        },
        {
            "name": "Decreased RBCs",
            "percent": "1-2"
        },
        {
            "name": "Increased CPK",
            "percent": "1-2"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "1-2"
        },
        {
            "name": "Myalgia",
            "percent": "1-2"
        },
        {
            "name": "Erythema",
            "percent": "1-2"
        },
        {
            "name": "Hypocalcemia",
            "percent": "1-2"
        },
        {
            "name": "Bradycardia",
            "percent": "7-10"
        },
        {
            "name": "Eye disorders",
            "percent": "1-6"
        },
        {
            "name": "Nausea",
            "percent": "2-6"
        },
        {
            "name": "Vomiting",
            "percent": "8-10"
        },
        {
            "name": "Incision site pain",
            "percent": "3-6"
        },
        {
            "name": "Procedural nausea",
            "percent": "5-8"
        },
        {
            "name": "Procedural vomiting",
            "percent": "3-6"
        }
    ]
}